Previous reports found that 20/29 (69%) and 10/12 (83%) of breast tumors from germline TP53 carriers had HER2 amplification or over-expression [20,21] and having a HER-amplified tumor increased the odds of having TP53 germline mutation by nearly seven-fold [21]. The gene discussed is ERBB2; the disease is neoplasm.